Clinical aspects and prospects of using DPP-4 inhibitors
https://doi.org/10.21518/2079-701X-2019-4-24-29
Abstract
Type 2 diabetes mellitus is a serious disease associated with the development of severe complications. Recent advances in diabetology are related to hormone therapy. The mechanism of action of DPP-4 inhibitors is discussed. The results of clinical studies of the efficacy and safety of gosogliptine are presented.
About the Author
E. V. Biryukova
Federal State Budgetary Educational Institution of the Higher Education «Moscow State University of Medicine and Dentistry named after A.I. Yevdokimov» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Biryukova Elena Valeryevna - Dr. of Sci. (Med), Professor of the Department of Endocrinology and Diabetology.
127473, Moscow, 20, Delegateskaya St., b. 1
References
1. Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I.I. Dedov, M.V. Shestakova, A.Yu. Mayorov. 9th issue. М., 2019. (In Russ.)
2. Schwartz S.S., Epstein S., Corkey B.E. et al. A Unified pathophysiological construct of diabetes and its complications. Trends Endocrinol Metab. 2017;28(9):645-655. doi: 10.1016/j.tem.2017.05.005.
3. Cantini G., Mannucci E., Luconi1 M. Perspectives in GLP-1 research: new targets, new receptors. Trends in Endocrinology & Metabolism. 2016;27(6):427-438. http//dx.doi.org/10.1016/j.tem.2016.03.017.
4. Chrysant S.G., Chrysant G.S. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol. 2012;109(11):1681-1685.
5. Johns E., McKay G., Fisher M. Dipeptidyl peptidase-4 (DPP-4) inhibitors. Br J Cardiol. 2017;24:(1). doi:10.5837/bjc.2017.001.
6. ADA Standards of Medical Care in Diabetes. Diabetes Care. 2018,41:S1-S156.
7. Bohannon N. Overview of the gliptin class (Dipeptidyl Peptidase-4 Inhibitors) in clinical practice. Postgraduate Medicine. 2009;121(1):1-6.
8. Carr R.D. Drug development from the bench to the pharmacy: with special reference to dipep-tidyl peptidase-4 inhibitor development. Diabet Med. 2016;33:718-722. doi: 10.1111/dme.13066.
9. Physiology of the Gastrointestinal Tract. Edited by H.M. Said. Elsevier Inc. All 2018.
10. Mkrtumyan A.M., Biryukova E.V. The use of incretines in the treatment of type 2 diabetes mellitus is a yesterday's dream, close to reality today. Saharnyj diabet. 2005;31(2): 34-41. (In Russ.)
11. D’Alessio D.A., Vahl T.P. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab. 2004;286:E882-E90.
12. Yabe D., Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Prog Biophys Mol Biol. 2011;107(2):248-256. doi: 10.1016/j.pbiomolbio.2011.07.010.
13. Gutniak M., Orskov C., Holst JJ., Ahren B., Efendic S. Antidiabetogenic effect of glucagonlike peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326:1316-1322. doi: 10.1056/NEJM199205143262003.
14. Ahren B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes Metab. 2013;39(3):195-201. doi: 10.1016/j.diabet.2013.03.001.
15. Ahren B. GLP-1 and extra-islet effects. Horm Metab Res. 2004;36(11-12):842-845.
16. Von Websky K., Reichetzeder C., Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens. 2014;23(1):54-60.
17. Kim N-H., Taeyang Yu T., Lee D.H. The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors. BioMed Research International. 2014:368703. http//dx.doi.org/10.1155/2014/368703.
18. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism. 2011;13:7-18.
19. Mannucci E., Pala L., Ciani S. et al. Hypergly-caemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005; 48(6): 1168-1172. doi: 10.1007/s00125-005-1749-8.
20. Da Silva Junior W.S., de Godoy-Matos A.F., Kraemer-Aguiar L.G. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis? BioMed Research International. 2015:816164. http//dx.doi.org/10.1155/2015/816164.
21. Schwartz S.L. Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010;8:405-18.
22. Duarte A.I., Candeias E., Correia S.C. et al. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim Biophys Acta. 2013;1832(4):527-541. doi: 10.1016/j.bbadis.2013.01.008.
23. http//www.remedium.ru/news/detail.php?ID=69136.
24. Galstyan K.O., Nedosugova L.V., Petunina N.A., et al. The first domestic inhibitor of DPP-4 gos-ogliptin in comparison with vildagliptin in the treatment of patients with type 2 diabetes mel-litus. Saharnyj diabet.2016;19(1):89-96. (In Russ.)
25. Aroda V.A., Henry R.R., Han J., Huang W. et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: Meta-analysis and systematic review. Clinical Therapeutics. 2012;34(6):1247-1258.
26. Shafiee G., Mohajeri-Tehrani M., Pajouhi M., Larijani B. The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord. 2012;11:17. doi: 10.1186/2251-6581-11-17.
Review
For citations:
Biryukova EV. Clinical aspects and prospects of using DPP-4 inhibitors. Meditsinskiy sovet = Medical Council. 2019;(4):24-29. (In Russ.) https://doi.org/10.21518/2079-701X-2019-4-24-29
Views:
664
Email this article 